María Teresa Martínez Martínez (María Teresa Martínez, María T Martinez)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Vascular Endothelial Growth Factor

Sentinel Lymph Node

Top Venues

International journal of molecular sciences

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Alejandra Rezqallah, Sara Torres-Esquius, Alba Llop-Guevara, Mara Cruellas, María Teresa Martínez Martínez, Marcel Romey, Carsten Denkert, Violeta Serra, Isabel Chirivella, Judith Balmaña
Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing. JCO precision oncology 8 (2024)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Marta Tapia, Cristina Hernando, María Teresa Martínez Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda-Roca, Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lluch, Begoña Bermejo, Pilar Eroles
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. Cancers 15 (18) (2023)
Francisco Ayala, Silvia Antolin Novoa, Joaquín Gavilá, Lucía González Cortijo, Fernando Henao, María Teresa Martínez Martínez, Cristina Morales Estévez, Agostina Stradella, María Jesús Vidal Losada, Eva Ciruelos Gil
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Francisco Ayala, Silvia Antolin Novoa, Joaquín Gavilá, Lucía González Cortijo, Fernando Henao, María Teresa Martínez Martínez, Cristina Morales Estévez, Agostina Stradella, María Jesús Vidal Losada, Eva Ciruelos Gil
Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer. International journal of molecular sciences 24 (4) (2023)
Birlipta Pattanayak, Ana Lameirinhas, Sandra Torres-Ruiz, Octavio Burgués, Ana Rovira, María Teresa Martínez Martínez, Marta Tapia, Sandra Zazo, Joan Albanell, Federico Rojo, Begoña Bermejo, Pilar Eroles
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway. International journal of molecular sciences 23 (21) (2022)
Anna Adam-Artigues, Enrique J Arenas Lahuerta, Alex Martínez-Sabadell, Fara Brasó-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, María Teresa Martínez Martínez, Juan Antonio Carbonell-Asins, Soraya Simón, Jesús Poveda, Santiago Moragón, Sandra Zazo, Débora Martínez, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Begoña Bermejo, Ana Lluch, Aleix Prat, Joaquín Arribas, Pilar Eroles, Juan Miguel Cejalvo
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Science advances 8 (20) (2022)
Aura Muntasell, Sònia Servitja, Mariona Cabo, Begoña Bermejo, Sandra Pérez-Buira, Federico Rojo, Marcel Costa-García, Oriol Arpí, Manuela Moraru, Laia Serrano, Ignasi Tusquets, María Teresa Martínez Martínez, Gemma Heredia, Andrea Vera, María Martínez-García, Laura Soria, Laura Comerma, Sara Santana-Hernández, Pilar Eroles, Ana Rovira, Carlos Vilches, Ana Lluch, Joan Albanell, Miguel López-Botet
High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer immunology research 7 (8) (2019)